File Download
There are no files associated with this item.
Links for fulltext
(May Require Subscription)
- Publisher Website: 10.1016/j.bpobgyn.2020.10.005
- Scopus: eid_2-s2.0-85094600570
- PMID: 33127305
- WOS: WOS:000672690200008
- Find via
Supplementary
- Citations:
- Appears in Collections:
Article: Surgery including fertility-sparing treatment of GTD
Title | Surgery including fertility-sparing treatment of GTD |
---|---|
Authors | |
Keywords | Gestational trophoblastic disease Gestational trophoblastic neoplasia Hydatidiform mole Surgery |
Issue Date | 2020 |
Publisher | Bailliere Tindall. The Journal's web site is located at http://www.elsevier.com/locate/bpobgyn |
Citation | Best Practice & Research: Clinical Obstetrics & Gynaecology, 2020, Epub 2020-10-10 How to Cite? |
Abstract | Gestational trophoblastic disease (GTD) consists of a spectrum of diseases, including hydatidiform moles, invasive mole, metastatic mole, choriocarcinoma, placental site trophoblastic tumour (PSTT) and epithelioid trophoblastic tumour (ETT). GTD is a relatively uncommon disease occurring in women of reproductive age, with high cure rates. Primary treatment of hydatidiform moles includes uterine evacuation, followed by close monitoring of serial hCG levels to detect for post-molar gestational trophoblastic neoplasia (GTN). In patients with GTN, the main therapy consists of chemotherapy, although some surgical procedures are important in selected patients to achieve curing. Hysterectomy is the mainstay treatment for PSTT or ETT and may be considered in selected patients for management of hydatidiform mole and malignant GTN especially in chemoresistant disease. Resection of metastatic lesions such as in the lung or brain can be considered in selected patients with isolated chemoresistant tumour. Surgical treatment of GTD will be discussed in this chapter. |
Persistent Identifier | http://hdl.handle.net/10722/294671 |
ISSN | 2023 Impact Factor: 3.9 2023 SCImago Journal Rankings: 1.532 |
PubMed Central ID | |
ISI Accession Number ID |
DC Field | Value | Language |
---|---|---|
dc.contributor.author | Ngu, SF | - |
dc.contributor.author | Ngan, HYS | - |
dc.date.accessioned | 2020-12-08T07:40:15Z | - |
dc.date.available | 2020-12-08T07:40:15Z | - |
dc.date.issued | 2020 | - |
dc.identifier.citation | Best Practice & Research: Clinical Obstetrics & Gynaecology, 2020, Epub 2020-10-10 | - |
dc.identifier.issn | 1521-6934 | - |
dc.identifier.uri | http://hdl.handle.net/10722/294671 | - |
dc.description.abstract | Gestational trophoblastic disease (GTD) consists of a spectrum of diseases, including hydatidiform moles, invasive mole, metastatic mole, choriocarcinoma, placental site trophoblastic tumour (PSTT) and epithelioid trophoblastic tumour (ETT). GTD is a relatively uncommon disease occurring in women of reproductive age, with high cure rates. Primary treatment of hydatidiform moles includes uterine evacuation, followed by close monitoring of serial hCG levels to detect for post-molar gestational trophoblastic neoplasia (GTN). In patients with GTN, the main therapy consists of chemotherapy, although some surgical procedures are important in selected patients to achieve curing. Hysterectomy is the mainstay treatment for PSTT or ETT and may be considered in selected patients for management of hydatidiform mole and malignant GTN especially in chemoresistant disease. Resection of metastatic lesions such as in the lung or brain can be considered in selected patients with isolated chemoresistant tumour. Surgical treatment of GTD will be discussed in this chapter. | - |
dc.language | eng | - |
dc.publisher | Bailliere Tindall. The Journal's web site is located at http://www.elsevier.com/locate/bpobgyn | - |
dc.relation.ispartof | Best Practice & Research: Clinical Obstetrics & Gynaecology | - |
dc.subject | Gestational trophoblastic disease | - |
dc.subject | Gestational trophoblastic neoplasia | - |
dc.subject | Hydatidiform mole | - |
dc.subject | Surgery | - |
dc.title | Surgery including fertility-sparing treatment of GTD | - |
dc.type | Article | - |
dc.identifier.email | Ngu, SF: ngusiewf@hku.hk | - |
dc.identifier.email | Ngan, HYS: hysngan@hkucc.hku.hk | - |
dc.identifier.authority | Ngu, SF=rp01367 | - |
dc.identifier.authority | Ngan, HYS=rp00346 | - |
dc.description.nature | link_to_OA_fulltext | - |
dc.description.nature | link_to_subscribed_fulltext | - |
dc.identifier.doi | 10.1016/j.bpobgyn.2020.10.005 | - |
dc.identifier.pmid | 33127305 | - |
dc.identifier.pmcid | PMC7547826 | - |
dc.identifier.scopus | eid_2-s2.0-85094600570 | - |
dc.identifier.hkuros | 320432 | - |
dc.identifier.volume | Epub 2020-10-10 | - |
dc.identifier.isi | WOS:000672690200008 | - |
dc.publisher.place | United Kingdom | - |